This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

This study has been completed.
Information provided by (Responsible Party):
Xichun Hu, Fudan University Identifier:
First received: July 27, 2012
Last updated: September 8, 2015
Last verified: September 2015
The objective of this phase II study is to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five patients will be enrolled into this study.

Condition Intervention Phase
Metastatic Breast Cancer Drug: Avastin + mFOLFOX6 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer

Resource links provided by NLM:

Further study details as provided by Xichun Hu, Fudan University:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: response evaluation every two cycles ]

Secondary Outcome Measures:
  • Number of adverse events [ Time Frame: 8 weeks ]

Enrollment: 72
Study Start Date: May 2012
Study Completion Date: November 2014
Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Avastin + mFOLFOX6
Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
Drug: Avastin + mFOLFOX6

mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2,ivgtt; Leucovorin 400 mg/m2,ivgtt; 5-FU 400 mg/m2,iv,and then 2400 mg/m2,civ46h;

Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w

Other Names:
  • Avastin
  • Oxaliplatin
  • Leucovorin
  • 5-FU

Detailed Description:
Anthracyclines and taxanes are the most frequently used agents for breast cancer,both in adjuvant and in first-line metastatic settings.For the patients who do not respond or relapse early after the administration of a taxane or anthracycline regimen,it is clearly needed to explore new combinations and schedules of drugs.Oxaliplatin has shown very promising activity in MBC either in monotherapy or in combination with 5-fluorouracil(5-FU) with or without leucovorin (LV). Avastin is a target therapy with proven efficacy in the treatment of MBC. Avastin plus FOLFOX regimen showed synergetic effet and been used as the standard trial in metastatic colorectal cancer patients. Based on the above reason, we initiate this phase II study to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. age>=18years
  2. Eastern Cooperative Oncology Group (ECOG) performance status (PS) <=2 and a life expectancy >= 12 weeks;
  3. histological-proven, HER-2 negative measurable stage IV disease;
  4. exposure to anthracyclines, taxanes either in the neoadjuvant/adjuvant or in the metastatic setting and had documented disease progression after the firstline or secondline treatment
  5. Patients previously treated with radiotherapy were eligible for the study, provided that measurable disease existed outside the radiation field.
  6. At least 3 weeks from the prior chemotherapy or radiotherapy. At least 2 weeks from the prior endocrine therapy.

Exclusion Criteria:

  1. Patients with active infection or other serious underlying medical conditions
  2. Patients had prior treatment with 5-FU infusion and/or oxaliplatin therapy
  3. Inadequate bone marrow, liver, renal, medullary, and cardiac functions
  4. Evidence of spinal cord compression or brain metastasis
  5. History of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer
  6. Pregnant or lactating women
  7. Serious uncontrolled intercurrent infection
  8. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
  9. Serious non-bleeding wound, peptic ulcer or bone fracture
  10. Prior dihypopyrimidine dehydrogenase deficiency
  11. Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanlised antibodies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01658033

China, Shanghai
Fudan University Cancer Hospital
Shanghai, Shanghai, China, 200032
Sponsors and Collaborators
Fudan University
Principal Investigator: Xichun Hu, PhD Medical Oncology Department
Principal Investigator: Xichun Hu, PhD Fudan University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Xichun Hu, Associate director of medical oncology department, Fudan University Identifier: NCT01658033     History of Changes
Other Study ID Numbers: Fudan BR2012-11
Study First Received: July 27, 2012
Last Updated: September 8, 2015

Keywords provided by Xichun Hu, Fudan University:
Metastatic Breast Cancer, Her-2 negative Breast Cancer
Avastin, FOLFOX regimen

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on September 21, 2017